Browsing Tag
immunology
24 posts
Why selective immune homeostasis is the bigger story behind CUE-401
Cue Biopharma’s CUE-401 data points to a bigger autoimmune story. Read why selective immune homeostasis could reshape immunology pipelines.
April 18, 2026
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race and what it means for biotech strategy, competition, and valuation. Read more.
April 16, 2026
Bristol Myers Squibb signs $1.1bn multi-specific antibody discovery deal with Harbour BioMed
Harbour BioMed signed a $1.125B discovery deal with Bristol Myers Squibb to co-develop multi-specific antibodies. Read the full strategic breakdown now.
December 17, 2025
What KT‑621 success could mean for oral immunology drugs and Kymera Therapeutics
Get ready for Kymera Therapeutics' KT‑621 Phase 1b data on December 8. Can this oral eczema drug change the future of immunology?
December 6, 2025
Nektar Therapeutics (NASDAQ: NKTR) rezpegaldesleukin shows dual action in skin and asthma — is this a pipeline turning point?
Nektar Therapeutics’ rezpegaldesleukin delivers dual efficacy in dermatitis and asthma in Phase 2b REZOLVE-AD trial. See how this Treg-based therapy is changing the game.
November 10, 2025
Bristol Myers Squibb’s CD19 NEX-T therapy shows 94% off immunosuppressants in early Phase 1 results
Bristol Myers Squibb’s CAR T cell therapy shows early promise in autoimmune disorders. Find out what the data means for the stock and the wider market.
October 25, 2025
Will Biogen’s $1bn bet on Vanqua Bio’s oral inflammation drug jumpstart its post-MS future?
Biogen’s $1.06B Vanqua Bio licensing deal signals a strategic shift toward immunology. Explore the roadmap behind this bold preclinical move.
October 25, 2025
Rani Therapeutics seals $1.085bn Chugai deal and $60m oversubscribed financing to fuel oral biologics push
Rani Therapeutics secured a $1.085 B Chugai collaboration and an oversubscribed $60.3 M raise. Find out how this dual deal could redefine its biotech trajectory.
October 17, 2025
Can AbbVie’s RINVOQ fill the biologics gap for IBD patients unsuitable for TNF therapy?
AbbVie gets FDA approval for broader RINVOQ use in IBD patients beyond TNF blockers. Find out how this impacts stock sentiment and investor expectations.
October 13, 2025
Johnson & Johnson (NYSE: JNJ) gains FDA approval to expand SIMPONI into pediatric ulcerative colitis
FDA approves SIMPONI (golimumab) for children ≥15 kg with ulcerative colitis, expanding Johnson & Johnson’s immunology portfolio. Learn what it means for patients.
October 8, 2025